Clinical Trial

Dapiglutide for the Treatment of Obesity

Study acronym: DREAM
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is an investigator-initiated, proof-of-concept, randomised, double-blind, placebo-controlled, parallel-group, single-centre clinical trial investigating the body weight loss potential of dapiglutide, a dual GLP-1R/GLP-2R agonist, administered subcutaneously once weekly. The study will investigate the efficacy of once-weekly subcutaneously administered of 4 mg and 6 mg dapiglutide versus placebo in 54 obese individuals (BMI \>30 kg/m2) during a 12-week treatment period.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-03-24; most recent amendment 2024-12-04.
Status change: Recruiting → Active, Not Recruiting 2024-01-03
Status change: Not Yet Recruiting → Recruiting 2023-05-08
Trial Details
NCT Number NCT05788601
Lead Sponsor University Hospital, Gentofte, Copenhagen
Collaborators: Zealand Pharma
Conditions Obesity, Inflammation
Enrollment 54 participants
Start Date 2023-04-27
Primary Completion 2024-04-24 (estimated)
Study Completion 2025-08-15 (estimated)
Updated on ClinicalTrials.gov 2024-12-05